Almac has enhanced its radiolabelling capabilities with a significant facility expansion.
The opening of the facility follows Almac's official accreditation for cGMP manufacturing and the securing an Investigational Medicinal Products (IMP) drug product-manufacturing licence from the Medicines and Healthcare Regulatory Agency (MHRA).
The expanded laboratories will include 20 new workstations - 14 synthesis and a further six general workstations for chemistry and analysis.
These facilities will be staffed by a team of radiochemists, including Dr Sean Kitson who received the 2006 Wiley Journal of Labelled Compounds and Radiopharmaceuticals Young Scientists award for his work on the elaborate radiosynthesis of the Parkinson's drug -(-)-[6a-14C]apomorphine.
The expanded facilities will also feature a dedicated manufacturing finishing suite for the development of IMPs used in clinical trials and the final steps in Active Pharmaceutical Ingredients (API) manufacture.
This will allow analytical chemists to carry out critical testing of a labelled IMP and undergo X-ray-powered diffraction (XRPD) to determine the degree of polymorphism, all on the same site.
